TesoRx Product Pipeline

TSX-049 is a novel, oral formulation of Testosterone (T) containing Testosterone Undecanoate (TU) that is designed to help restore normal T levels in males with hypogonadism. We believe our product would be successful in treating age related hypogonadism. The successful completion of a confirmative study in canines was designed to predict the pharmacokinetic profile of TSX-049 for the oral treatment of hypogonadism.

The results of the study confirmed that the optimized TSX-049 formulation has enhanced bioavailability and a dose response sufficient to overcome negative feedback of gonadal testosterone production. TesoRx will be advancing TSX-049 into Phase 1-2a human clinical trials and anticipates a potential U.S. Food and Drug Administration approval in early 2026.